vs
Protagonist Therapeutics, Inc（PTGX）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BRC Group Holdings, Inc.的季度营收约是Protagonist Therapeutics, Inc的1.1倍（$188.3M vs $170.6M），Protagonist Therapeutics, Inc净利率更高（77.2% vs 47.9%，领先29.2%），Protagonist Therapeutics, Inc同比增速更快（184.4% vs -21.9%）
Protagonist Therapeutics是一家临床阶段生物制药公司，专注于研发创新肽类靶向疗法，以满足胃肠道疾病、炎症性疾病及罕见病领域未被满足的医疗需求，核心候选产品覆盖炎症性肠病等慢性免疫相关适应症。
PTGX vs RILY — 直观对比
营收规模更大
RILY
是对方的1.1倍
$170.6M
营收增速更快
PTGX
高出206.3%
-21.9%
净利率更高
PTGX
高出29.2%
47.9%
损益表 — Q4 FY2024 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $170.6M | $188.3M |
| 净利润 | $131.7M | $90.3M |
| 毛利率 | — | 79.5% |
| 营业利润率 | 74.3% | 32.3% |
| 净利率 | 77.2% | 47.9% |
| 营收同比 | 184.4% | -21.9% |
| 净利润同比 | 381.7% | 1710.8% |
| 每股收益（稀释后） | $2.01 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PTGXRILY
| Q4 25 | — | $188.3M | ||
| Q3 25 | — | $215.3M | ||
| Q2 25 | — | $188.2M | ||
| Q1 25 | — | $197.2M | ||
| Q4 24 | $170.6M | $241.0M | ||
| Q3 24 | — | $225.5M | ||
| Q2 24 | — | $256.0M | ||
| Q1 24 | $255.0M | $263.4M |
净利润PTGXRILY
| Q4 25 | — | $90.3M | ||
| Q3 25 | — | $91.1M | ||
| Q2 25 | — | $139.5M | ||
| Q1 25 | — | $-10.0M | ||
| Q4 24 | $131.7M | $-5.6M | ||
| Q3 24 | — | $-284.4M | ||
| Q2 24 | — | $-433.6M | ||
| Q1 24 | $207.3M | $-49.2M |
毛利率PTGXRILY
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | — | 81.3% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
营业利润率PTGXRILY
| Q4 25 | — | 32.3% | ||
| Q3 25 | — | 30.4% | ||
| Q2 25 | — | 5.7% | ||
| Q1 25 | — | -31.2% | ||
| Q4 24 | 74.3% | -69.2% | ||
| Q3 24 | — | -36.4% | ||
| Q2 24 | — | -90.8% | ||
| Q1 24 | 80.9% | -6.1% |
净利率PTGXRILY
| Q4 25 | — | 47.9% | ||
| Q3 25 | — | 42.3% | ||
| Q2 25 | — | 74.1% | ||
| Q1 25 | — | -5.1% | ||
| Q4 24 | 77.2% | -2.3% | ||
| Q3 24 | — | -126.1% | ||
| Q2 24 | — | -169.4% | ||
| Q1 24 | 81.3% | -18.7% |
每股收益（稀释后）PTGXRILY
| Q4 25 | — | $2.78 | ||
| Q3 25 | — | $2.91 | ||
| Q2 25 | — | $4.50 | ||
| Q1 25 | — | $-0.39 | ||
| Q4 24 | $2.01 | $-0.01 | ||
| Q3 24 | — | $-9.39 | ||
| Q2 24 | — | $-14.35 | ||
| Q1 24 | $3.26 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $418.9M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $675.3M | $-171.5M |
| 总资产 | $744.7M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PTGXRILY
| Q4 25 | — | $226.6M | ||
| Q3 25 | — | $184.2M | ||
| Q2 25 | — | $267.4M | ||
| Q1 25 | — | $138.3M | ||
| Q4 24 | $418.9M | $146.9M | ||
| Q3 24 | — | $159.2M | ||
| Q2 24 | — | $236.9M | ||
| Q1 24 | $322.6M | $190.7M |
总债务PTGXRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益PTGXRILY
| Q4 25 | — | $-171.5M | ||
| Q3 25 | — | $-260.5M | ||
| Q2 25 | — | $-351.7M | ||
| Q1 25 | — | $-496.8M | ||
| Q4 24 | $675.3M | $-488.2M | ||
| Q3 24 | — | $-497.6M | ||
| Q2 24 | — | $-218.3M | ||
| Q1 24 | $560.4M | $228.4M |
总资产PTGXRILY
| Q4 25 | — | $1.7B | ||
| Q3 25 | — | $1.7B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | $744.7M | $1.8B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $3.2B | ||
| Q1 24 | $629.3M | $5.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $184.2M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $182.8M | — |
| 自由现金流率自由现金流/营收 | 107.1% | — |
| 资本支出强度资本支出/营收 | 0.8% | — |
| 现金转化率经营现金流/净利润 | 1.40× | 0.29× |
| 过去12个月自由现金流最近4个季度 | $101.7M | — |
8季度趋势，按日历期对齐
经营现金流PTGXRILY
| Q4 25 | — | $26.2M | ||
| Q3 25 | — | $-60.6M | ||
| Q2 25 | — | $-25.6M | ||
| Q1 25 | — | $184.0K | ||
| Q4 24 | $184.2M | $-2.7M | ||
| Q3 24 | — | $19.5M | ||
| Q2 24 | — | $111.5M | ||
| Q1 24 | $-27.4M | $135.4M |
自由现金流PTGXRILY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $182.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-27.7M | — |
自由现金流率PTGXRILY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 107.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -10.9% | — |
资本支出强度PTGXRILY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.1% | — |
现金转化率PTGXRILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.40× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.13× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PTGX
暂无分部数据
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
